In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Feeling less stigma — not losing weight — was linked to better mental health, eating behaviors and weight loss after ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

Many women can truly relate to this specific moment happening. Perhaps you were speaking to people, or just bent low to tie ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

The executive director, Matthew Veno, said the commission is on track to run out of ... last June for weight loss. It’s only cost him a $25 monthly co-pay under his Blue Cross plan provided ...

Finding a sustainable path to weight ... mask fat loss temporarily. Monitoring progress through multiple metrics helps maintain perspective during these normal variations. Take monthly progress ...

U.S. stocks were rising toward the closing bell on Friday, but all three major benchmarks were on track to wrap up February with monthly losses amid worries over slowing growth and sticky inflation.

The medication can be taken monthly by injection and resulted in an average weight loss of up to 20% over 52 weeks, according to data released by the company. Unlike other treatments, MariTide has ...

Injectable GLP-1 agonists have gained popularity as a breakthrough solution for individuals struggling to shed excess weight ... Body composition tracking is another key to look for in a responsible ...

Metsera links long-acting GLP-1 shot to 7.5% weight loss at 36 days, mulls monthly dosing The monthly ... or overweight is fully enrolled and on track to deliver data around the middle of 2025.